Icosavax Announces Positive Topline Interim Phase 1 Results

–  IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – –  IVX-A12 was generally well tolerated with no vaccine-related... | May 22, 2023

Related Keywords

United States , Jessica Yingling , Adam Simpson , Laurence Watts , Niranjan Kanesa Thasan , Institute For Protein Design , Nasdaq , Globenewswire Inc , University Of Washington , Little Dog Communications Inc , Exchange Commission , Icosavax Inc , Gilmartin Group , Chief Executive Officer , Chief Medical Officer , Protein Design , Private Securities Litigation Reform Act , Icosavax , Nc Stock Exchange , News , Information , Press Release , Induced , Obust , Immune , Responses , It , Bay , 8 , O , Moth , Rsv , End , Mpv , N , Ilder , Gas , Igenerally , Fell , Ctolerated , Ith , O Icvx Us45114m1099 ,